March 29, 2019

March 29, 2019

Saliva HPV Test Ready for Prime Time in Head and Neck Cancer?

MedPage Today – March 28

In the sample of over 200 men with oropharyngeal squamous cell carcinoma (OPSCC), the assay was able to detect HPV genotypes in 82.8% of patients using saliva compared with 93.0% with p16 immunostaining of tumor tissue, Christine H. Chung, MD, of Moffitt Cancer Center in Tampa, Florida, and colleagues reported.

 

The Patient Journey When Receiving Innovative Therapy: Improving Care in Real Time

Journal of Clinical Pathways – March 27

The session was moderated by Frederick L Locke, MD (Moffitt Cancer Center, Program Co-Leader, Immunology), who treated Jeffrey Backerm MD, FACEP, when he was approved for the ZUMA-1 trial in May 2016. Also part of this discussion was nurse coordinator at Moffitt, Alix Beaupierre, BSN, RN, OCN.

 

Moffitt CEO to be inducted into the 2019 Florida Inventors Hall of Fame

Tampa Bay Business Journal – March 27

President and CEO of Moffitt Cancer Center, Dr. Alan List, is being inducted into the 2019 Florida Inventors Hall of Fame for developing new therapeutic strategies for treating blood cancers.

 

USF Alum Joanna Fowler, Faculty Member Alan List Inducted into Florida Inventors Hall of Fame

Tampa Bay Newswire – March 27

University of South Florida alumna Joanna Fowler, whose pioneering work in molecular imaging was recognized with a National Medal of Science, and Moffitt Cancer Center CEO and President Alan List are among eight diverse and transformative inventors announced as the 2019 inductees of the Florida Inventors Hall of Fame.

 

Moffitt CEO, Hollywood icon join Florida Inventors Hall of Fame

St. Pete Catalyst – March 26

Alan List, CEO and president of H. Lee Moffitt Cancer Center & Research Institute in Tampa, and Hedy Lamarr, a movie star whose invention helped enable WiFi, GPS and Bluetooth, are among the eight new inductees in the Florida Inventors Hall of Fame.

 

Florida Inventors Hall of Fame announces 2019 inductees

Eurekalert – March 26

Alan List, CEO and president of H. Lee Moffitt Cancer Center & Research Institute in Tampa selected for his dedication to understanding cancer biology and developing novel therapeutic strategies for treating hematologic malignancies such as myelodysplastic syndrome (MDS) and acute myelocytic leukemia (AML). List is an NAI Fellow and holds six U.S. patents.

 

ASH Reports Show Benefit of Adding Daratumumab to Initial Therapy in Multiple Myeloma

The ASCO Post – March 25

Daratumamab appears to be the “gift that keeps on giving” to the myeloma community. “It seems we can add daratumumab to almost anything and make the regimen better. It’s got good activity and a good safety profile,” said Kenneth Shain, MD, PhD, Director of the Myeloma Working Group at Moffitt Cancer Center, Tampa, who commented on the benefit observed by adding the monoclonal antibody to doublets and triplets in trials described at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition.

 

How Jaqueline’s Promise and Persistence Paid Off

Melanoma Research Alliance – March 2019

During this recurrence, Jacqueline consulted a plastic surgeon in New York City. She recalls the encounter vividly, “He told me, ‘If you were my daughter, I would take you to Moffitt Cancer Center, so that’s where I suggest you go and if you are ever offered a clinical trial, promise me that you’ll take it.

 

A Clever New Strategy for Treating Cancer, Thanks to Darwin

Wired – March 25

When Robert Gatenby heard this history of the diamond­back moth in 2008, he immediately latched onto it. Gatenby is not a farmer nor an agronomist nor a fan of cruciferous vegetables—in fact, he deeply loathes Brussels sprouts. He is a radiologist by training and heads the radiology department at the H. Lee Moffitt Cancer Center in Tampa, Florida. But unlike your typical doctor, he is also obsessed with the evolutionary principles put forth more than 150 years ago by Charles Darwin. 

 

Healthcare In The Age Of Personalization Part 3: How Business Models Must Evolve

Forbes – March 24

Dr. List: Certainly value-based care is something that [Moffitt has] been leading in nationally, in the oncology space. We do one thing – cancer research and cancer care – and at least on the care delivery outside of clinical trials, we wanted to be at the table with the insurers when all of this began.

 

Free Cancer Screenings during Spring Training Day

Bay News 9 – March 23

It’s called Spring Swing and it's the final event of the season. Moffitt Cancer Center will be offering the free screenings from 10:30-1 p.m. when the Toronto Blue Jays take on the Canada Junior Team at Dunedin Stadium. 

 

Frederick L. Locke, MD, on Innovative CAR-T Cell Therapies: The Patient Experience

ASCO Post – March 23

Frederick L. Locke, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses recent approvals of chimeric antigen receptor T-cell therapies in leukemia and lymphoma, and how clinicians are using infrastructure, navigation, and early referrals to maximize response and minimize toxicity.

 

Tampa Pride returns March 30

WFTS – March 24

One of the things we'll be go doing in the festival is a free health fair. We have Moffitt Cancer Center, Tampa General Hospital, Metro Inclusive Health doing free testing so you can get your free test, cancer screenings. We have around 40 different vendors just in the health area.

 

Key Trials Seek to Expand on Efficacy, Tolerability of Treatment Regimens in Refractory CRC

OncLive – March 22

At the meeting, Iman Imanirad, a medical oncologist at Moffitt Cancer Center, discussed these trials in depth and their impact on patients with refractory metastatic CRC.

 

ER Doc Survives Cancer, Now Must Survive ER

Medscape – March 22

Also sharing the stage at the NCCN meeting, Frederick Locke, MD, a hematologist-oncologist at Moffitt Cancer Center in Tampa, Florida, and one of a team that uses CAR T-cell therapy, beamed: "We're glad you are here with us."

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.